MedTrace Logo

WithDRawal Impact Of Postoperative Beta-Blocker

NCT05414331 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2025-04-06

No results posted yet for this study

Summary

The investigators will evaluate the impact of withdrawing beta-blocker medication after coronary artery bypass surgery with this randomized controlled trial.

Conditions

  • Coronary Artery Bypass

Interventions

OTHER

Discontinuing all beta-blocker

All beta-blockers will be stopped 2 months after CABG

Sponsors & Collaborators

  • Glenn Memorial Fund

    collaborator UNKNOWN

  • Yale University

    lead OTHER

Principal Investigators

  • Arnar Geirsson, MD · Yale University

  • Makoto Mori, MD · Yale University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-04
Primary Completion
2024-05-02
Completion
2024-05-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05414331 on ClinicalTrials.gov